ADIM
ANIP icon

Alpha DNA Investment Management’s ANI Pharmaceuticals ANIP Stock Holding History

Alpha DNA Investment Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9,627
Closed -$559K – 187
2023
Q3 		$559K Sell
9,627
-4,093
-30% -$236K 0.23% 109
2023
Q2 		$739K Buy
+13,720
New +$608K 0.25% 127

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alpha DNA Investment Management's ANIP Position: Q4 2023 in Review

Alpha DNA Investment Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2023, closing a stake of 9,627 shares — an estimated $559K sold.

Alpha DNA Investment Management first reported a position in ANIP in Q2 2023 and held it in 2 quarters. The position peaked at $739K in Q2 2023. 181 funds tracked by Wall St. Rank hold ANIP as of Q4 2023.

  • Alpha DNA Investment Management reported no remaining ANI Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 9,627 ANI Pharmaceuticals shares in Q4 2023, an estimated $559K.
  • Alpha DNA Investment Management first reported a position in ANI Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Alpha DNA Investment Management's ANI Pharmaceuticals position peaked at $739K in Q2 2023.
  • 181 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2023.

Based on Alpha DNA Investment Management's 13F filing for Q4 2023, filed 12 Feb 2024.